INMARSAT
23.5.2023 09:01:35 CEST | Business Wire | Press release
Inmarsat has announced the next chapter of its market-leading Jet ConneX (JX) inflight broadband solution, with a new range of service plans introduced to redefine gold standard connectivity in the business aviation market and satisfy even the most data-hungry users for many years to come.
Launched as part of Inmarsat’s JX Evolution programme, these latest service plans are available for new and existing customers to order today, marking a step-change in performance that is backed by guaranteed speeds and Inmarsat’s hallmark consistent customer experience.
The new service plans offer enhanced performance using Jet ConneX’s existing, highly successful JetWave terminal by Inmarsat’s partner Honeywell, and will also be compatible with three upcoming next-generation terminals being developed by Satcom Direct, Orbit and Honeywell. Satcom Direct’s Plane Simple Ka-band system has commenced flight testing and is expected to enter service later this year.
All three next-generation terminals use innovative technology and lightweight designs to optimise performance, reduce costs, and simplify installation and maintenance. Their reduced size and weight make them suitable for various types of business jets, creating new opportunities in the fast-growing super midsize aircraft market, which shares many of the same connectivity requirements as large aircraft.
Jet ConneX customers will also benefit from seven more Inmarsat satellite payloads entering service by 2025, increasing its Ka-band network fleet to 12. This includes two Inmarsat-6s, both of which have already launched, followed by two payloads in highly elliptical orbit, enabling the world’s only commercial mobile broadband service for flights in higher latitudes and across the Arctic. Three additional satellites will then launch in geostationary orbit, adding further speed, capacity, and resilience.
The combination of next generation terminals and Inmarsat’s fast-growing satellite network will enable speeds up to 100 Mbps, for top tier customers that demand the highest level ‘office-in-the-sky’ experience.
The new Jet ConneX service plans are available through Inmarsat’s global business aviation distribution network, which consists of Satcom Direct, Collins Aerospace and Honeywell.
Kai Tang, Inmarsat’s Head of Business Aviation, said “Jet ConneX is renowned for delivering a very high standard of service and these transformative new plans once again highlight Inmarsat’s continued focus on staying ahead of market expectations. This provides customers with reassurance that our connectivity will keep pace with their long-term needs. Importantly, as these include the first plans to use our new satellites and terminals, it also offers a glimpse into future capabilities and provides certainty that their investment in our technology is future-proofed.
“These service plans have been specifically designed to deliver even greater value and performance based on unique insights into usage of our inflight broadband service. This build-up approach is unique to Inmarsat and cannot be replicated by others in the market, some of which have a tendency to over promise and under deliver, either from the start or as their networks fill and performance degrades.
“Crucially, this is only the next step for us. We will continue to assess usage and adapt accordingly, with even more flexible options to be announced later this year.”
Since entering commercial service in November 2016, Jet ConneX has been activated on more than 1,400 business jets: offering the same reliable, consistent and high-speed broadband that was previously only available on the ground. Passenger usage of Jet ConneX increased to record levels since the pandemic, testament to fast-growing expectations from users, who use everything from video streaming and live TV to conference calls and other business activities. JX’s most powerful service plans will now enable passengers to simultaneously connect more devices and enjoy unchallenged access to the most data-hungry applications - including high-definition video conferencing - without compromising on its proven characteristics of consistency, reliability, resilience, and seamless global availability.
Inmarsat’s 2023 global survey of business aviation professionals - conducted in partnership with Corporate Jet Investor (CJI) - found that 82% of respondents believe inflight connectivity has evolved from a luxury option for some, to a key requirement for the majority of passengers. The results, published at the European Business Aviation Convention & Exhibition (EBACE) this week, show the three most important factors when selecting a connectivity system, in order, were consistent performance, 100% route coverage, and high speed.
ENDS
ABOUT INMARSAT
Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.
In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.
For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005098/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
